Accelerator-based boron neutron capture therapy for recurrent head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I study tests accelerator-based boron neutron capture therapy (BNCT) using intravenous L‑Boronophenylalanine and the nuBeam Suite in adults with locally recurrent head and neck carcinoma after prior radiotherapy. The primary goal is to demonstrate the safety and tolerability of delivering BNCT with the accelerator system, and secondary goals include confirming planned dose delivery and the functionality of trial treatment planning software and robotic CT-based positioning. Patients will receive L‑BPA infusion followed by targeted neutron irradiation with careful dosimetry, imaging-guided positioning, and monitoring for adverse events and tumor response. The trial is sponsored by Neutron Therapeutics in collaboration with Helsinki University Hospital and is conducted at Helsinki University Hospital in Finland.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patient considered for the study has provided a written informed consent as approved by the EC prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
2. ≥ 18 years of age at the time of enrollment.
3. Histologically confirmed head and neck carcinoma.
4. Inoperable cancer, prior surgery may or may not have been done.
5. Prior radiotherapy or chemoradiotherapy has been given.
6. Anticipated life expectancy of at least 6 months.

Exclusion Criteria:

Patients who fulfill any of the following criteria will be excluded:

1. Presence of distant metastases.
2. World Health Organization (WHO) performance status \> 2 (see Appendix 2).
3. Concurrent uncontrolled localized cancer other than head and neck carcinoma or overtly metastatic cancer.
4. The patient has access to a non-experimental, effective treatment option and is a suitable candidate for such therapy.
5. Concomitant chemotherapy.
6. Concurrent experimental therapy or participation in a trial with an experimental therapy within 3 months prior to study inclusion.
7. Less than 3 months since prior radiation therapy.
8. Major surgery within 4 weeks prior to study inclusion.
9. Unremovable metal implants present in the head and neck region that will interfere with CT/MRI-based dose-planning.
10. Known sensitivity to the study drug.
11. One or more of the following:

    * Blood hemoglobin \< 100 g/L, neutrophils \< 1.5 x 109/L, platelet count \< 120 x 109/L
    * Serum/plasma creatinine \> 1.5 x Upper Limit of Normal (ULN)
    * Serum bilirubin 2.0 \> ULN
    * Serum ALT and/or AST \> 2.0 x ULN
    * Serum alkaline phosphatase \> 2.5 x ULN
12. Serious uncontrolled infection or other serious uncontrolled concomitant disease.
13. Collagen vascular disease or a disease that is considered to increase radiosensitivity of normal tissues to radiation (e.g., ataxia-telangiectasia)
14. The patient is unwilling or unable to comply with the CIP required follow-up visits for the duration of the study.
15. Untreated or severe treated congestive heart failure, cardiac pacemaker, or renal failure.
16. Restlessness or inability to lie in a cast for about 30 minutes.
17. Clinical follow-up after therapy cannot be arranged or the patient is not willing to participate in the follow-up.
18. Known pregnancy, breastfeeding, or planning of pregnancy; for women of childbearing potential, a negative urine pregnancy test must be obtained prior to enrollment.
19. The patient is not able to understand the nature of the study and trial treatment options.
20. Phenylketonuria.
21. Fructose intolerance.

Where it's running

• Helsinki University Hospital
  Helsinki, Finland Recruiting

Study contacts

• Study coordinator: Anu Anttonen, MD, PhD
• Email: anu.anttonen@hus.fi
• Phone: 358 50 4279911

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intraoperative Methadone for Postoperative Pain in Head and Neck Cancer Patients

  This trial tests whether giving methadone during surgery, in addition to standard fentanyl, helps control pain after head and neck cancer surgery more effectively than fentanyl alone.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07857655

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Tongue-out positioning to lower mouth and swallowing side effects in head and neck cancer

  This trial will try a 'tongue-out' position during radiation to see if it lowers mouth sores, taste changes, and swallowing problems for people with oropharyngeal, laryngeal, or hypopharyngeal squamous cell carcinoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07227792

• Using virtual reality to help improve mental health and pain in head and neck cancer patients and their caregivers

  This study is testing if a special virtual reality program can help improve mental health and reduce pain for people with head and neck cancer and their caregivers during treatment.

  Recruiting City of Hope Medical Center · Duarte, California · NCT06985784

• Financial Compass intervention for head and neck cancer patients facing financial hardship

  This study is testing a new program called Financial Compass to see if it can help head and neck cancer patients who are struggling with money feel more supported compared to regular care.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT06896695

• Pre-surgery metronidazole and chlorhexidine to lower bacteria in oral cavity tumors

  This study will try a short course of the antibiotic metronidazole plus chlorhexidine mouthwash before surgery to see if it lowers bacteria inside tumors in adults with oral squamous cell carcinoma.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06627270

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.